Hino H, Oda Y, Yoshida Y, Suzuki T, Shimada M, Nishikawa K
Department of Anesthesiology, Osaka City General Hospital, Osaka, Japan.
Department of Pediatric Electrophysiology, Pediatric Medical Care Center, Osaka City General Hospital, Osaka, Japan.
Acta Anaesthesiol Scand. 2018 Feb;62(2):159-166. doi: 10.1111/aas.13023. Epub 2017 Oct 25.
We hypothesized that, compared with propofol, desflurane prolongs the antegrade accessory pathway effective refractory period (APERP) in children undergoing radiofrequency catheter ablation for Wolff-Parkinson-White (WPW) syndrome.
In this randomized crossover study, children aged 4.1-16.1 years undergoing radiofrequency catheter ablation for WPW syndrome were randomly divided into four groups according to the concentration of desflurane and anesthetics used in the first and the second electrophysiological studies (EPS). After induction of general anesthesia with propofol and tracheal intubation, they received one of the following regimens: 0.5 minimum alveolar concentration (MAC) desflurane (first EPS) and propofol (second EPS) (Des0.5-Prop group, n = 8); propofol (first EPS) and 0.5 MAC desflurane (second EPS) (Prop-Des0.5 group, n = 9); 1 MAC desflurane (first EPS) and propofol (second EPS) (Des1.0-Prop group, n = 10); propofol (first EPS) and 1 MAC desflurane (second EPS) (Prop-Des1.0 group, n = 9). Radiofrequency catheter ablation was performed upon completion of EPS. Sample size was determined to detect a difference in the APERP.
Desflurane at 1.0 MAC significantly prolonged the APERP compared with propofol, but did not affect the sinoatrial conduction time, atrio-His interval or atrioventricular node effective refractory period. Supraventricular tachycardia was induced in all children receiving propofol, but not induced in 1 and 4 children receiving 0.5 MAC and 1.0 MAC desflurane, respectively.
Desflurane enhances the refractoriness and may block the electrical conduction of the atrioventricular accessory pathway, and is therefore not suitable for use in children undergoing radiofrequency catheter ablation for WPW syndrome.
我们假设,与丙泊酚相比,地氟醚可延长接受 Wolff-Parkinson-White(WPW)综合征射频导管消融术的儿童的前向附加旁道有效不应期(APERP)。
在这项随机交叉研究中,将接受 WPW 综合征射频导管消融术的 4.1 - 16.1 岁儿童,根据首次和第二次电生理研究(EPS)中使用的地氟醚浓度和麻醉剂,随机分为四组。在丙泊酚诱导全身麻醉并气管插管后,他们接受以下方案之一:0.5 最低肺泡浓度(MAC)地氟醚(首次 EPS)和丙泊酚(第二次 EPS)(Des0.5 - Prop 组,n = 8);丙泊酚(首次 EPS)和 0.5 MAC 地氟醚(第二次 EPS)(Prop - Des0.5 组,n = 9);1 MAC 地氟醚(首次 EPS)和丙泊酚(第二次 EPS)(Des1.0 - Prop 组,n = 10);丙泊酚(首次 EPS)和 1 MAC 地氟醚(第二次 EPS)(Prop - Des1.0 组,n = 9)。EPS 完成后进行射频导管消融术。样本量确定为检测 APERP 的差异。
与丙泊酚相比,1.0 MAC 的地氟醚显著延长了 APERP,但不影响窦房传导时间、心房 - 希氏束间期或房室结有效不应期。所有接受丙泊酚的儿童均诱发了室上性心动过速,但接受 0.5 MAC 和 1.0 MAC 地氟醚的儿童中,分别有 1 例和 4 例未诱发。
地氟醚可增强不应性,并可能阻断房室附加旁道的电传导,因此不适合用于接受 WPW 综合征射频导管消融术的儿童。